keyword
MENU ▼
Read by QxMD icon Read
search

Levodopa

keyword
https://www.readbyqxmd.com/read/28928050/predictors-of-onset-of-psychosis-in-patients-with-parkinson-s-disease-who-gets-it-early
#1
Abhishek Lenka, Lija George, Shyam Sundar Arumugham, Shantala Hegde, Venkateswara Reddy, Nitish Kamble, Ravi Yadav, Pramod Kumar Pal
INTRODUCTION: Psychosis is one of the common non-motor symptoms of PD, which substantially worsens the quality of life. Hence, it is important to identify factors that are associated with early onset of psychosis in PD. In order to identify those factors, the current study aims to compare various demographic and clinical features of PD patients with early and late onset psychosis. METHODOLOGY: In this prospective case-control study, 51 consecutive patients with PD having psychosis (PDP) were recruited...
September 14, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28927418/a-systematic-review-and-integrative-approach-to-decode-the-common-molecular-link-between-levodopa-response-and-parkinson-s-disease
#2
Debleena Guin, Manish Kumar Mishra, Puneet Talwar, Chitra Rawat, Suman S Kushwaha, Shrikant Kukreti, Ritushree Kukreti
BACKGROUND: PD is a progressive neurodegenerative disorder commonly treated by levodopa. The findings from genetic studies on adverse effects (ADRs) and levodopa efficacy are mostly inconclusive. Here, we aim to identify predictive genetic biomarkers for levodopa response (LR) and determine common molecular link with disease susceptibility. A systematic review for LR was conducted for ADR, and drug efficacy, independently. All included articles were assessed for methodological quality on 14 parameters...
September 19, 2017: BMC Medical Genomics
https://www.readbyqxmd.com/read/28923293/two-polysomnographic-features-of-rem-sleep-behavior-disorder-clinical-variations-insight-for-parkinson-s-disease
#3
Yun Shen, Yong-Ping Dai, Yi Wang, Jie Li, Kang-Ping Xiong, Cheng-Jie Mao, Jun-Ying Huang, Wei-Feng Luo, Chun-Feng Liu
INTRODUCTION: Loss of REM sleep muscle atonia (RWA) and dream-enactment behavior (DEB) are two associated features of REM sleep behavior disorder (RBD), which is frequently associated with Parkinson's disease (PD). Few studies have examined both DEB and RWA simultaneously in patients with PD. This study aimed to evaluate relationships between RWA, DEB and clinical characteristics of PD. METHODS: We conducted overnight polysomnography in 145 patients with PD. DEB (motor behaviors and/or vocalizations during REM) and increased RWA (IRWA; tonic and phasic chin EMG density ≥ 30% and ≥15%, respectively) were identified...
September 5, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28922612/analysis-of-levodopa-content-in-commercial-mucuna-pruriens-products-using-high-performance-liquid-chromatography-with-fluorescence-detection
#4
Amala Soumyanath, Tanya Denne, Amie Hiller, Shaila Ramachandran, Lynne Shinto
OBJECTIVES: Mucuna pruriens (MP) seeds contain levodopa (up to 2% by weight) and have been used in traditional Indian medicine to treat an illness named "Kampavata," now understood to be Parkinson's disease (PD). Studies have shown MP to be beneficial, and even superior, to levodopa alone in treating PD symptoms. Commercial products containing MP are readily available from online and retail sources to patients and physicians. Products often contain extracts of MP seeds, with significantly higher levodopa content than the seeds...
September 18, 2017: Journal of Alternative and Complementary Medicine: Research on Paradigm, Practice, and Policy
https://www.readbyqxmd.com/read/28920562/comparison-of-general-and-local-anesthesia-for-deep-brain-stimulator-insertion-a-systematic-review
#5
Veena Sheshadri, Nathan C Rowland, Jigesh Mehta, Marina Englesakis, Pirjo Manninen, Lashmi Venkatraghavan
BACKGROUND: Subthalamic nucleus deep brain stimulation (STN-DBS) has become a standard treatment for many patients with Parkinson's disease (PD). The reported clinical outcome measures for procedures done under general anesthesia (GA) compared to traditional local anesthetic (LA) technique are quite heterogeneous and difficult to compare. The aim of this systematic review and metaanalysis was to determine whether the clinical outcome after STN-DBS insertion under GA is comparable to that under LA in patients with Parkinson's disease...
September 18, 2017: Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques
https://www.readbyqxmd.com/read/28918694/brain-metabolic-correlates-of-fatigue-in-parkinson-s-disease-a-pet-study
#6
Li Zhang, Tiannv Li, Yongsheng Yuan, Qing Tong, Siming Jiang, Min Wang, Jianwei Wang, Jian Ding, Qinrong Xu, Kezhong Zhang
The neural bases of fatigue in Parkinson's disease (PD) remain uncertain. We aimed to assess the brain metabolic correlates of fatigue in patients with PD. Twenty-seven PD patients without clinically relevant depression (17-item Hamilton Depression Rating Scale [HAMD] score ≥ 14), apathy (Apathy Scale [AS] score ≥ 14) and excessive daytime somnolence (Epworth Sleepiness Scale [ESS] score ≥ 10) were evaluated with Fatigue Severity Scale (FSS). Each patient had an F-18 fluorodeoxyglucose PET (FDG-PET) scan...
September 18, 2017: International Journal of Neuroscience
https://www.readbyqxmd.com/read/28904985/cholinergic-activity-and-levodopa-induced-dyskinesia-a-multitracer-molecular-imaging-study
#7
Joachim Brumberg, Sebastian Küsters, Ehab Al-Momani, Giorgio Marotta, Kelly P Cosgrove, Christopher H van Dyck, Ken Herrmann, György A Homola, Gianni Pezzoli, Andreas K Buck, Jens Volkmann, Samuel Samnick, Ioannis U Isaias
OBJECTIVE: To investigate the association between levodopa-induced dyskinesias and striatal cholinergic activity in patients with Parkinson's disease. METHODS: This study included 13 Parkinson's disease patients with peak-of-dose levodopa-induced dyskinesias, 12 nondyskinetic patients, and 12 healthy controls. Participants underwent 5-[(123)I]iodo-3-[2(S)-2-azetidinylmethoxy]pyridine single-photon emission computed tomography, a marker of nicotinic acetylcholine receptors, [(123)I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography, to measure dopamine reuptake transporter density and 2-[(18)F]fluoro-2-deoxyglucose positron emission tomography to assess regional cerebral metabolic activity...
September 2017: Annals of Clinical and Translational Neurology
https://www.readbyqxmd.com/read/28904448/surgical-treatment-of-levodopa-induced-dyskinesia-in-parkinson-s-disease
#8
Syam Krishnan, Krishnakumar Kesava Pisharady
The treatment of motor manifestations of Parkinson's disease (PD) is essentially a trade-off between adequate relief of motor symptoms and prevention and control of motor complications, particularly levodopa-induced dyskinesia (LID). Progression of PD is paralleled by a progressive difficulty in achieving the balance. Functional neurosurgical procedures provide sustained relief of LID in carefully selected patients when further tailoring of medical therapy fails to achieve this goal. Though deep brain stimulation (DBS) has superseded lesioning surgeries, pallidotomy still has a role in those patients in whom DBS is not feasible for financial or other reasons...
July 2017: Annals of Indian Academy of Neurology
https://www.readbyqxmd.com/read/28904447/levodopa-induced-dyskinesia-clinical-features-pathophysiology-and-medical-management
#9
Sanjay Pandey, Prachaya Srivanitchapoom
Levodopa-induced dyskinesia (LID) is commonly seen in Parkinson's disease patients treated with levodopa. This side effect is usually encountered after long duration of treatment, but occasionally, this may be seen even after few days or months of treatment. LID is broadly classified as peak-dose dyskinesia, wearing-off or off-period dyskinesia, and diphasic dyskinesia. Pathogenesis of LID is complex, and different neurotransmitters such as dopamine, glutamine, adenosine, and gamma-aminobutyric acid play important role altering the normal physiology of direct and indirect pathway of cortico-basal ganglia-thalamic loop responsible for fine motor control...
July 2017: Annals of Indian Academy of Neurology
https://www.readbyqxmd.com/read/28904446/levodopa-history-and-therapeutic-applications
#10
Sujith Ovallath, Bahiya Sulthana
Levodopa - the aromatic amino acid L-3,4-dihydroxy phenylalanine has held the attention of neurologists and pharmacologists alike for more than half a century. Even though extensive research has been done across the globe in treatment of Parkinson's disease, with different molecules, none could replace the gold standard treatment or provide complete relief for the debilitated. Although research brought us better tips and tricks to modulate the dopamine blood levels to balance between the desired and deleterious effects, it could never replace the basic substrate...
July 2017: Annals of Indian Academy of Neurology
https://www.readbyqxmd.com/read/28900068/-efficacy-of-topical-agents-for-symptomatic-treatment-of-rotigotine-patch-induced-skin-disorders
#11
Yuki Yasutaka, Shinsuke Fujioka, Hirotomo Shibaguchi, Fumiaki Kiyomi, Koyomi Hara, Kentaro Ogata, Yoshio Tsuboi, Hidetoshi Kamimura
Since the effect of a percutaneous absorption-type dopamine agonist (DA) preparation, rotigotine patch, stably persists by once-a-day application, this dosage form is appropriate for Parkinson's disease patients showing levodopa induced wearing off phenomenon. On the other hand, skin disorders, mainly application site reaction, are characteristic problems associated with use of the patch. In this study, to clarify the influence of a topical agent used to prevent or treat rotigotine patch-induced skin disorder on continuation of the patch application, patients who started rotigotine patch application at our hospital were retrospectively surveyed...
September 2017: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://www.readbyqxmd.com/read/28898256/carbidopa-a-drug-in-use-for-management-of-parkinson-disease-inhibits-t-cell-activation-and-autoimmunity
#12
Huabin Zhu, Henrique Lemos, Brinda Bhatt, Bianca N Islam, Abhijit Singh, Ashish Gurav, Lei Huang, Darren D Browning, Andrew Mellor, Sadanand Fulzele, Nagendra Singh
Carbidopa is a drug that blocks conversion of levodopa to dopamine outside of central nervous system (CNS) and thus inhibits unwanted side effects of levodopa on organs located outside of CNS during management of Parkinson's Disease (PD). PD is associated with increased expression of inflammatory genes in peripheral and central nervous system (CNS), infiltration of immune cells into brain, and increased numbers of activated/memory T cells. Animal models of PD have shown a critical role of T cells in inducing pathology in CNS...
2017: PloS One
https://www.readbyqxmd.com/read/28895769/the-cost-effectiveness-of-levodopa-carbidopa-intestinal-gel-compared-to-standard-care-in-advanced-parkinson-s-disease
#13
Julia Lowin, Kavita Sail, Rakhi Baj, Yash J Jalundhwala, Thomas S Marshall, Henrietta Konwea, K R Chaudhuri
BACKGROUND: Parkinson's disease (PD) is an incurable, progressive neurological condition, with symptoms impacting movement, walking and posture that eventually become severely disabling. Advanced PD (aPD) has a significant impact on quality of life (QoL) for patients, their caregivers/families. Levodopa/carbidopa intestinal gel (LCIG) is indicated for the treatment of advanced levodopa-responsive PD with severe motor fluctuations and hyper-/dyskinesia when available combinations of therapy have not given satisfactory results...
September 12, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28893517/differential-effects-of-levodopa-and-apomorphine-on-neuronal-population-oscillations-in-the-cortico-basal-ganglia-loop-circuit-in-vivo-in-experimental-parkinsonism
#14
Johanna Kühn, Jens K Haumesser, Maximilian H Beck, Jennifer Altschüler, Andrea A Kühn, Vadim N Nikulin, Christoph van Riesen
The current pharmacotherapy of Parkinson's disease (PD) is primarily based on two classes of drugs: dopamine precursors, namely levodopa, and dopamine receptor agonists, such as apomorphine. Although both types of agents exert their beneficial clinical effects on motor and non-motor symptoms in PD via dopamine receptors, clinical efficiency and side effects differ substantially between levodopa and apomorphine. Levodopa can provide a greater symptomatic relief than dopamine receptor agonists. However, because long-term levodopa use is associated with early debilitating motor fluctuations, dopamine receptor agonists are often recommended in younger patients...
September 8, 2017: Experimental Neurology
https://www.readbyqxmd.com/read/28892570/dnajc12-and-dopa-responsive-non-progressive-parkinsonism
#15
Letizia Straniero, Ilaria Guella, Roberto Cilia, Laura Parkkinen, Valeria Rimoldi, Alexander Young, Rosanna Asselta, Giulia Soldà, Vesna Sossi, A Jon Stoessl, Alberto Priori, Kenya Nishioka, Nobutaka Hattori, Jordan Follett, Alex Rajput, Nenad Blau, Gianni Pezzoli, Matthew J Farrer, Stefano Goldwurm, Ali H Rajput, Stefano Duga
Biallelic DNAJC12 mutations were described in children with hyperphenylalaninemia, neurodevelopmental delay, and dystonia. We identified DNAJC12 homozygous null variants (c.187A>T;p.K63*and c.79-2A>G;p.V27Wfs*14) in two kindreds with early-onset parkinsonism. Both probands had mild intellectual disability, mild non-progressive, motor symptoms, sustained benefit from small dose of levodopa and substantial worsening of symptoms after levodopa discontinuation. Neuropathology (Proband-A) revealed no alpha-synuclein pathology and substantia nigra depigmentation with moderate cell loss DNAJC12 transcripts were reduced in both patients...
September 11, 2017: Annals of Neurology
https://www.readbyqxmd.com/read/28891435/ninety-day-local-tolerability-and-toxicity-study-of-nd0612-a-novel-formulation-of-levodopa-carbidopa-administered-by-subcutaneous-continuous-infusion-in-minipigs
#16
Yuval Ramot, Abraham Nyska, Robert R Maronpot, Ronit Shaltiel-Karyo, Yonit Tsarfati, Rosa Anna Manno, Giuseppe Sacco, Oron Yacoby-Zeevi
A 90-day study in Göttingen minipigs was conducted to test the local tolerability and systemic toxicity of ND0612, a novel aqueous solution of carbidopa (CD)/levodopa (LD) intended for the treatment of Parkinson's disease by continuous subcutaneous administration using a discrete infusion pump. To evaluate tissue site reactions, we used a unique study design involving multiple infusion sites to evaluate the effect of dose per site (270/63, 360/45, and 360/84 mg LD/CD), volume of infusion per site (4.5 and 6 ml per site), formulation concentration (60/14 and 60/7...
January 1, 2017: Toxicologic Pathology
https://www.readbyqxmd.com/read/28890930/parkinson-s-disease-associated-with-pure-atxn10-repeat-expansion
#17
Birgitt Schüle, Karen N McFarland, Kelsey Lee, Yu-Chih Tsai, Khanh-Dung Nguyen, Chao Sun, Mei Liu, Christie Byrne, Ramesh Gopi, Neng Huang, J William Langston, Tyson Clark, Francisco Javier Jiménez Gil, Tetsudo Ashizawa
Large, non-coding pentanucleotide repeat expansions of ATTCT in intron 9 of the ATXN10 gene typically cause progressive spinocerebellar ataxia with or without seizures and present neuropathologically with Purkinje cell loss resulting in symmetrical cerebellar atrophy. These ATXN10 repeat expansions can be interrupted by sequence motifs which have been attributed to seizures and are likely to act as genetic modifiers. We identified a Mexican kindred with multiple affected family members with ATXN10 expansions...
2017: NPJ Parkinson's Disease
https://www.readbyqxmd.com/read/28888928/an-update-on-new-and-unique-uses-of-botulinum-toxin-in-movement-disorders
#18
Joseph Jankovic
The therapeutic applications of botulinum toxin (BoNT) have grown manifold since its initial approval in 1989 by the US Food and Drug Administration (FDA) for the treatment of strabismus, blepharospasm, and other facial spasms. Although it is the most potent biologic toxin known to man, long-term studies have established its safety in the treatment of a variety of neurologic and non-neurologic disorders. This review focuses on some novel and uncommon uses of BoNT in the treatment of movement disorders, such as oromandibular dystonia, including bruxism, anterocollis, camptocormia, tremor, tics, tardive and levodopa-induced dyskinesia, and restless legs syndrome...
September 6, 2017: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/28880414/levodopa-treatment-and-dendritic-spine-pathology
#19
REVIEW
Haruo Nishijima, Tatsuya Ueno, Yukihisa Funamizu, Shinya Ueno, Masahiko Tomiyama
Parkinson's disease (PD) is a neurodegenerative disorder associated with the progressive loss of nigrostriatal dopaminergic neurons. Levodopa is the most effective treatment for the motor symptoms of PD. However, chronic oral levodopa treatment can lead to various motor and nonmotor complications because of nonphysiological pulsatile dopaminergic stimulation in the brain. Examinations of autopsy cases with PD have revealed a decreased number of dendritic spines of striatal neurons. Animal models of PD have revealed altered density and morphology of dendritic spines of neurons in various brain regions after dopaminergic denervation or dopaminergic denervation plus levodopa treatment, indicating altered synaptic transmission...
September 7, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28879087/chronic-exposure-to-dopamine-agonists-affects-the-integrity-of-striatal-d2-receptors-in-parkinson-s-patients
#20
Marios Politis, Heather Wilson, Kit Wu, David J Brooks, Paola Piccini
We aimed to investigate the integrity and clinical relevance of striatal dopamine receptor type-2 (D2R) availability in Parkinson's disease (PD) patients. We studied 68 PD patients, spanning from early to advanced disease stages, and 12 healthy controls. All participants received one [(11)C]raclopride PET scan in an OFF medication condition for quantification of striatal D2R availability in vivo. Parametric images of [(11)C]raclopride non-displaceable binding potential were generated from the dynamic [(11)C]raclopride scans using implementation of the simplified reference tissue model with cerebellum as the reference tissue...
2017: NeuroImage: Clinical
keyword
keyword
14511
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"